☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Applied Therapeutics
Applied Therapeutics Receives Complete Response Letter for Govorestat’s NDA for Treating Classic Galactosemia
November 28, 2024
Applied Therapeutics Reports the US FDA’s Acceptance of NDA with Priority Review for Govorestat to Treat Classic Galactosemia
February 29, 2024
Applied Therapeutics Reports Results for Govorestat (AT-007) in P-III Trial for the Treatment of Sorbitol Dehydrogenase (SORD) Def...
February 17, 2024
Applied Therapeutics Reports P-III trial (INSPIRE) Results of AT-007 for Sorbitol Dehydrogenase Deficiency
February 17, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.